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ABSTRACT 
Objectives   
A human papillomavirus (HPV) vaccination programme targeted towards men who have sex with 
men (MSM) who are disproportionately affected by HPV ano-genital infection and related disease 
was established in Scotland in July 2017. We aimed to establish a baseline HPV prevalence to assess 
the potential impact of the programme. 
Methods  
Residual rectal swabs taken in a sexual health clinic (n=1248) were tested for the presence of HPV 
and HPV type prevalence was collated and stratified by age. Prevalence of HPV types included in the 
quadrivalent and nonavalent vaccines were specifically assessed.  
Results  
72.8% (95% CI 70.2-75.3%) of swabs were positive for HPV with 59.1% (95% CI 56.3-61.9%) of 
samples positive for at least one high risk type. A least one of HPV 6, 11, 16 and 18 were detected in 
approximately half of the swabs.  HPV prevalence generally increased with age but did not 
significantly differ between older age groups. The presence of more than one HPV type increased 
with age and over half of samples had multiple types present.  
Conclusions 
While HPV prevalence in this population is high, the potential impact of the vaccination programme 
is substantial given that 50% are not infected with a vaccine type. Defining a pre-immunisation 
baseline in this group will be important for longitudinal monitoring of impact.  
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INTRODUCTION  
A human papillomavirus (HPV) immunisation programme for gay, bisexual and other men who have 
sex with men (MSM) up to age 45 was introduced in Scotland in July 2017, in addition to the school- 
based vaccination programme targeting girls implemented in 2008. MSM are now routinely offered 
the quadrivalent HPV vaccine through sexual health clinics and most are offered a three dose 
schedule. The programme was initiated based on advice from the UK Joint Committee on 
Vaccination and Immunisation (JCVI), which recognised that MSM receive little benefit from the 
current national female only HPV programme while being at excess risk of HPV associated 
disease.[1]   
High-risk HPV infection is responsible for 90% of anal cancer, of which over 80% are associated with 
HPV 16 infection. HPV ano-genital infection and related disease is disproportionately higher in MSM 
who are 20 times more likely than heterosexual men to develop anal cancer. Additionally, the 
incidence of HPV-related oropharyngeal cancer is increasing in high-income countries in all men.[2,3] 
Genital warts are also one of the most common sexually transmitted diseases and can have 
debilitating social, sexual and psychological effects for affected individuals with 50% of patients 
having another episode of genital warts within one year of clearance.[4] The potential beneficial 
impact of the HPV immunisation programme for MSM is therefore considerable.   
We tested residual rectal swabs from men for HPV to establish a proxy baseline prevalence of HPV in 
MSM before the introduction of the immunisation programme to support the potential impact of 
the programme on HPV-infection and associated disease in this group.  
METHODS  
The rectal swabs included in the study were collected between October 2016 and February 2017 and 
taken from men who attended for an asymptomatic sexual health screen or for treatment of a 
presumed sexually transmitted infection. The samples were taken in a sexual health clinic within 
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NHS Lothian, a National Health Service (NHS) Scotland health board which covers 16% of the Scottish 
population and includes the City of Edinburgh and surrounding counties. The rectal swabs were 
clinician collected and originally taken for routine Chlamydia trachomatis and Neisseria gonorrhoeae 
testing using the Abbott RealTime CT/NG assay (Abbott Laboratories, Abbott Park, IL, USA).  
HPV DNA was extracted from 1 ml aliquots of residual swab material and  genotyped by the Scottish 
HPV Reference Laboratory using the Optiplex HPV Genotyping Kit (Diamex, Heidelberg, Germany) 
which detects 24 types including low-risk types.  HPV types 
16/18/31/33/35/39/45/51/52/56/58/59/68 were considered high-risk in line with the International 
Agency for Research on Cancer (IARC) classifications. Thirty-eight samples were insufficient for HPV 
testing due to too little residual sample or endogenous control failure.   
The genotyping results were collated along with basic demographic details and a study identifier. 
Assessment of type specific prevalence of HPV 6, 11, 16 and 18 was performed (types within the 
quadrivalent vaccine). Additionally, type specific prevalence of the aforementioned types and HPV 
31, 33, 45, 52 and 58 was also assessed as these are the types present in the nonavalent vaccine 
which may be utilised in the future. Analysis was performed centrally at Health Protection Scotland 
using R studio version 3.4.1 and Microsoft Excel 2007. A linear trend test was used to assess 
evidence for a linear trend in positivity of selected combined HPV types by age group.  
RESULTS  
Overall, 1210 samples were included in the final analysis. The highest proportion of samples were 
from men aged 45 years and older (282, 23.3%), followed by 21-25 year olds (237, 19.6%) and 26-30 
year olds (197, 16.3%). The mean age of the men from which the samples were taken was 36 years 
old (range 18-88 years old). The results of C. trachomatis and N. gonorrhoeae testing of the swabs 
were obtained and <1% were positive for C. trachomatis and none for N. gonorrhoeae.   
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Table one presents the overall and age-specific prevalence of different HPV types. Overall, 72.8% of 
samples were positive for HPV with 59.1% of samples positive for at least one high risk type. HPV 16 
was the most commonly detected HPV type. At least one HPV type covered by the quadrivalent 
vaccine  was present in just under half of the samples (49.6%) while 57.9% of samples contained at 
least one HPV type covered by the nonavalent vaccine with detections being high across all age 
groups with the exception of the youngest age group. The prevalence of HPV 6, 11, 16 and 18 
individually was 15.3% (95% CI 13.3-17.4%), 7.4% (95% CI 6.0-9.1%), 33.4% (95% CI 30.7-36.1%) and 
7.6% (95% CI 6.2-9.2%) respectively. Prevalence of the five types included in the nonavalent vaccine 
in addition to the types in the quadrivalent vaccine ranged between 3.6% (95% CI 2.7%-4.9%) for 
HPV 58 and 7.9% (95% CI 6.4-9.5%) for HPV 45.  
Prevalence of any HPV type increased linearly with increasing age group (p<0.001). This linear 
pattern was also observed for high-risk types (p<0.0001)  and HPV 16 and 18 (p<0.001) but was not 
observed for HPV 6 and 11 in which prevalence was highest in the 21-25 year old age group 
(p=0.8355). Prevalence of any HPV did not differ significantly between age groups older than 16-20 
years. HPV 6 and 11 were most prevalent in the 21-25 year old age group but not significantly so 
compared to other age groups. HPV 16 was the most common HPV type across each age group with 
the exception of the 16-20 year old age group in which no HPV type predominated.  No increasing 
linear trend was observed by increasing age in any of the HPV types in the quadrivalent vaccine 
other than HPV 16.  
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Table 1: Prevalence (%) (95% CI) of combinations of HPV types from rectal swab samples by age group 
Prevalence (%) (95% CI) of combinations of HPV types from rectal swab samples by age group 
 Any HPV High-risk HPV* Nonavalent† Quadrivalent‡ HPV 16/18 HPV 6/11 
Total  
(n=1210) 72.8 (70-75.3) 59.1 (56.3-61.9) 57.9 (55.0-60.7) 49.6 (46.7-52.4) 38.0 (35.3-40.8) 21.6 (19.3-24.0) 
       
16-20 years 
(n=55) 52.7 (38.8-66.3) 30.9 (19.1-44.8) 34.5 (22.2-48.6) 30.9 (19.1-44.8) 14.5 (6.5-26.7) 16.4 (7.8-28.8) 
21-25 years 
(n=237) 70.0 (63.8-75.8) 54.9 (48.3-61.3) 57.0 (50.4-63.4) 51.9 (45.3-58.4) 37.1 (31.0-43.6) 30.8 (25.0-37.1) 
26-30 years 
(n=197) 70.1 (63.1-76.4) 54.3 (47.1-61.4) 50.3 (43.1-57.4) 43.1 (36.1-50.4) 32.0 (25.5-39.0) 18.3 (13.1-24.4) 
31-35 years 
(n=192) 77.6 (71.0-83.3) 66.7 (59.5-73.3) 64.1 (56.8-70.8) 52.1 (44.8-59.3) 43.2 (35.4-51.7) 18.2 (13.0-24.4) 
36-40 years 
(n=152) 71.7 (63.8-78.7) 59.9 (51.6-67.7) 58.6 (50.3-66.5) 52.0 (43.7-60.1) 43.4 (35.4-51.7) 19.1 (13.2-26.2) 
41-45 years 
(n=95) 75.8 (65.9-84.0) 68.4 (58.1-77.6) 65.3 (54.8-74.7) 53.7 (43.2-64.0) 44.2 (34.0-54.8) 17.9 (10.8-27.1) 
>45 years 
(n=282) 77.3 (72.0-82.1) 62.8 (56.8-68.4) 61.3 (55.4-67.1) 51.4 (45.4-57.4) 39.0 (33.3-45.0) 22.0 (17.2-27.3) 
*High-risk HPV (HPV 16, 18, 31, 33, 45, 51, 52, 56, 58 and 59). †Nonavalent (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58). ‡Quadrivalent (HPV 6, 11, 16 and 18). 
 
 
 
 
7 
 
Over half of samples (52.1% 95% CI 49.2-55%) were positive for more than one HPV type. Of these, 
34.9% (95% CI 31.1-38.7%) were positive for two HPV types and 27.6% (95% CI 24.1-31.2%) were 
positive for three types. The percentage of samples in which more than one HPV type was present 
increased with increasing age (p<0.001).  
DISCUSSION 
Our study is the first to estimate HPV prevalence in rectal swabs from males attending sexual health 
clinics in Scotland and will be used as a baseline to compare prevalence after the introduction of the 
MSM HPV vaccination programme. Prevalence of any HPV in rectal swabs in the present study was 
high and comparable to  data assessed in a systematic review and meta-analysis that estimated 
rectal HPV prevalence in HIV-negative MSM and HIV-positive MSM as 63.9% (95% CI 55.2-72.6%) 
and 92.6% (95% CI 90.8-94.5%) respectively.[5] Prevalence of at least one quadrivalent vaccine type  
(49.6%)was higher compared to a study undertaken in a London sexual health clinic which found a 
prevalence of 29.1% in rectal swabs and may be due to inclusion of men over 40 in our study.[6]   
Prevalence of HPV generally increased by age but did not significantly differ between the older age 
groups which is consistent with an Australian study which hypothesised that continued HPV 
acquisition occurs later in life due to ongoing sexual activity with multiple partners in older MSM.[7] 
This pattern was not observed for HPV 6/11 prevalence which is reflected in data from Australia 
which showed that anal wart prevalence is highest in younger MSM. This is possibly related to 
increased susceptibility of the anal epithelium or lack of acquired immunity in younger MSM to HPV 
6 and 11.[8]   
There are limitations to our study including the nature and size of the sample which was captured at 
a single health board in Scotland. While, the generalisability of our findings to the wider Scottish 
MSM community could be compromised this may be mitigated somewhat by the fact that the health 
board in question is the second largest in Scotland.   
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 Additionally, confirmation of sexual identity was not proactively obtained from the men from whom 
the swabs were taken; however the likely indication for a rectal swab in a sexual health setting is 
considered a suitable marker for someone who engages in receptive anal sex.[9] HIV status of the 
sampled men was known for <10% of samples and sexual history data was not available; therefore 
risk status could not be assessed. The low prevalence of C. trachomatis and N. gonorrhoeae may 
suggest that our sample was from a lower risk population or that the majority of samples were taken 
during an asymptomatic sexual health screen.   
The fact that around 50% of the sample did not test positive for an HPV type included in the 
quadrivalent vaccine suggests that the HPV immunisation programme targeting MSM in Scotland has 
the potential to significantly reduce HPV-driven disease. A HPV negative sample does not exclude 
previous HPV infection and the benefit of the vaccine may be lower in previously infected 
individuals, however, even these individuals may benefit from the vaccine as they would be 
protected from further exposures to other HPV types in the vaccine in which they are naïve to. [7] 
Nonavalent vaccine would be even more beneficial in this respect if offered in the future. Early trial 
results have shown the quadrivalent vaccine is associated with a reduction in all grades of anal 
intraepithelial neoplasia (AIN) in MSM.[10] Taken with our results and others, the offer of the HPV 
vaccine to MSM over the age of 45 years may also be beneficial.  HPV typing of rectal swab and 
throat swab samples following initiation of the HPV programme in MSM and analysis of prescriptions 
for genital warts in the future will further enable the impact assessment of the HPV vaccine in MSM. 
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